Tyler Goodwin, PhD

Head of Delivery Technologies at Tune Therapeutics

Speaker

Tyler Goodwin, Ph.D., has spent the last 15 years developing viral and nonviral based vectors to deliver a variety of biomolecules from DNA, RNA, and peptides across a wide range of applications including vaccines, gene replacement, gene editing, and epigenetic modulation. He completed his doctoral studies at the University of North Carolina (UNC). Following his academic training, Dr. Goodwin contributed to cutting-edge research and development at Precision Bioscience, a company known for its work in gene editing and cell therapy. He further expanded his professional experience as the Drug Product Lead at Kriya Therapeutics, and then as a Senior Consultant at Biotechlogic (Dark Horse Consulting). Currently, Dr. Goodwin is the Head of Delivery at Tune Therapeutics, focused on developing therapies utilizing Tunes proprietary epigenetic modulation platform TEMPO.

Dr. Goodwin has been involved in advancing innovative approaches to genetic therapies, leveraging his strong foundation in research and biotechnology to contribute to the development of novel treatments. His work aims to bridge the gap between scientific discovery and practical therapeutic applications, making him an emerging leader in the field of precision medicine.